Skip to content

Outcomes and Perceptions of the Implementation of the JADA Device in a Stage II Postpartum Hemorrhage Management Protocol in Referral Hospitals of the Colombian Pacific Region

Outcomes and Perceptions of the Implementation of the JADA Device in a Stage II Postpartum Hemorrhage Management Protocol in Referral Hospitals of the Colombian Pacific Region: a Cohort Study

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06843265
Acronym
JADAValle
Enrollment
24
Registered
2025-02-24
Start date
2025-06-01
Completion date
2025-12-31
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Partum Haemorrhage

Keywords

maternal mortality, Shock Index, care bundle

Brief summary

This study focuses on postpartum hemorrhage (PPH), a condition that stands out as the leading cause of global maternal mortality. Annually, about 14 million women experience PPH, resulting in approximately 70,000 deaths. This condition presents a higher risk in low- and middle-income countries (LMICs), particularly where access to quality care is limited. Recognizing the urgency of addressing this public health problem, the Colombian Ministry of Health and Social Protection has implemented the Maternal Mortality Reduction Acceleration Plan (PARE) to improve maternal mortality indicators and meet the Sustainable Development Goals (SDGs). The project will evaluate the results and perception of a new device in the management of stage II PPH in referral hospitals in the department of Valle del Cauca, integrated in the Hospital Padrino strategy. This initiative seeks not only to improve the understanding and treatment of PPH, but also to strengthen institutional capacities through education, creation of telecare networks and care services adapted to local needs.

Interventions

DEVICEVacuum- Induce Hemorrhage Control

The JADA System is designed for single use only and is composed of medical grade silicone. Its components include an intrauterine loop with protected vacuum pores, a cervical seal with a sealing valve for infusing saline and a vacuum connector port for applying suction. The intrauterine loop is located at the distal end of a tube and contains 20 protected vacuum pores oriented inward along the loop. This shielded design facilitates intracavitary suction by shielding maternal tissue from the vacuum source and prevents clogging of the vacuum pores with tissue or clot.

Sponsors

Hospital Universitario del Valle Evaristo Garcia
CollaboratorUNKNOWN
Fundacion Clinica Valle del Lili
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Pregnant women who are admitted to the obstetrics service scheduled for vaginal delivery in any of the participating hospitals: Fundación Valle del Lili, Hospital Universitario del Valle and Hospital Luis Ablanque de la Plata. * Patient admitted during the shift of one of the gynecologists trained in the use of the JADA device in the context of the research project. Criteria for the use of JADA device: * Pregnant women over or equal to 18 years of age. * Gestational age of pregnancy greater than 32 weeks of gestation. * Pregnant with vaginal delivery. * Pregnant with postpartum hemorrhage due to uterine atony that does not respond to treatment with uterotonics and uterine massage. * Postpartum hemorrhage uterine stage/stage II. * Vaginal delivery attended in a health institution in the context of the Hospital Padrino strategy (Fundación Valle del Lili or Hospital Universitario del Valle or Hospital Luis Ablanque de la Plata).

Exclusion criteria

* Patients who, according to the attending physician's criteria, are not candidates for vaginal delivery. * Abnormality of the normal uterine anatomy. * Placental abnormalities. * Maternal anemia with hemoglobin less than 7 mg/dl prior to delivery. * Those who do not sign informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Bleeding controlup to 42 days postpartumPostpartum hemorrhage defined as quantified bleeding of more than 500 ml for vaginal deliveries and more than 1000 ml for cesarean deliveries, occurring within the first 24 h after delivery and which may be associated with signs of hemodynamic instability, i.e. the ratio between heart rate and systolic blood pressure (shock index). Following this concept of the shock index and the amount of bleeding, the stages of postpartum hemorrhage are divided, which, according to the result of the shock index, the therapy is directed: Stage 1: Bleeding 500-1000 cc, Shock index of \<0.9, bleeding time \<10 minutes. Stage 2: Bleeding 1000-1500 cc, shock index 0.9-1.4 bleeding time 10-20 minutes. Stage 3: Bleeding \<1500 cc, shock index \>1.5, bleeding time greater than 20 minutes. Stage 4: Cardiovascular collapse with profound hypovolemic shock and coagulopathy. These stages will be measured through a bag which will fulfill the function of measuring to indicate the stage and amount of bleeding

Contacts

Primary ContactMaria F Escobar, Gynecologist and Obstetrician
maria.escobar.vi@fvl.org.co+57 315 433 1584

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026